Major Shareholder Threatens Legal Action After Opposing 61% Dilution at AGM
PRQR is trading near its 52-week low of $1.33 (11% above the low).
Summary
A 14.6% shareholder, Van Herk Investments, is threatening legal action against ProQR Therapeutics and its board after publicly opposing the recently approved proposals for significant share dilution and expanded board authority.
Key Events · Ownership and Investor Activity · PRQR
-
Shareholder Activism
Van Herk Investments, holding 14.6% of shares, filed an amendment to their Schedule 13D detailing their opposition to management's proposals.
-
Opposition to Dilution
The investor group publicly opposed AGM agenda items 7, 8, and 9, which sought to increase authorized capital and grant the board broad authority to issue shares, citing potential 61% dilution.
-
Threat of Legal Action
Van Herk Investments has retained counsel and is evaluating initiating legal proceedings against the company, board, and officers to protect shareholder interests.
-
Governance Concerns
The investor group highlighted existing governance deficiencies, including the chairman's tenure and multiple board positions, as reasons for their opposition.
Analysis · PRQR · Life Sciences
A significant shareholder, Van Herk Investments (14.6% stake), has escalated its opposition to ProQR's management by threatening legal proceedings against the company, its board, and officers. This follows their public opposition to recent AGM proposals, which were ultimately approved, granting the board broad authority to issue new shares and potentially dilute existing shareholders by up to 61%. The investor group cites governance deficiencies and a lack of justification for such extensive powers. This signals a deepening conflict between a major investor and company leadership, potentially leading to costly litigation and further instability.
At the time of this filing, PRQR was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $154.9M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.